XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
89.30
-0.15 (-0.17%)
At close: 4:00PM EDT

89.30 0.00 (0.00%)
After hours: 4:46PM EDT

Stock chart is not supported by your current browser
Previous Close89.45
Open89.09
Bid89.13 x 1200
Ask89.45 x 800
Day's Range87.43 - 89.38
52 Week Range78.46 - 101.55
Volume3,668,889
Avg. Volume4,003,329
Net Assets5.36B
NAV95.93
PE Ratio (TTM)N/A
Yield0.23%
YTD Return13.19%
Beta (3Y Monthly)1.80
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Using electric fields to fight cancer
    Yahoo Finance Video2 months ago

    Using electric fields to fight cancer

    Senator John McCain will be laid to rest this weekend, after losing his battle Saturday with glioblastoma, an aggressive form of brain cancer. Yahoo Finance's Dion Rabouin and Maylan Studart talk to Novocure Executive Chairman, Bill Doyle about its treatment that uses electric fields to fight cancer growth.

  • All-Time highs: 6 stocks to buy
    CNBC Videos2 months ago

    All-Time highs: 6 stocks to buy

    The "Fast Money" traders give you 6 trades as the U.S. stock market hits all time highs.

  • Final Trade: AXP, XBI & more
    CNBC Videos3 months ago

    Final Trade: AXP, XBI & more

    The "Fast Money" traders share their final trades of the day, including American Express, the XBI biotech ETF, Sabra Health Care REIT and Twitter.

  • TheStreet.com6 days ago

    Square Continues to See Extreme Pressure

    The easy trade this morning would have been a big emotional gap down open but every algorithm out there was ready to buy that setup so they ended up buying before the open instead. The big bounce in futures occurred in the two hours before the open and undercut the easy 'buy the dip' setup.

  • 10 Best ETFs for 2018: Still a Close Race at the Head of the Pack
    InvestorPlace7 days ago

    10 Best ETFs for 2018: Still a Close Race at the Head of the Pack

    Welcome to the final quarter of the 2018 Best ETFs contest, which is, admittedly, also our first Best ETFs contest.

  • Investopedia7 days ago

    Biotech Gearing Up for a Pullback?

    There has been no shortage of encouraging news over the past few months across the biotech sector, but the patterns that are appearing on several key charts are suggesting that the story could be in the early stages of shifting. Active traders who are looking for exposure to biotechnology often turn to exchange-traded products such as the SPDR S&P Biotech ETF. As you can see from the chart below, the price has been trading along a well-defined trendline over the past couple of years, but the recent close below the trendline suggests that the ETF is in the early stages of a downtrend.

  • A Look at Portola Pharmaceuticals’ Financial Performance
    Market Realist9 days ago

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.

  • Cara Therapeutics: Performance and Estimates for Q3
    Market Realist12 days ago

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

  • Ionis Pharmaceuticals’ Revenue Growth Rate
    Market Realist14 days ago

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.

  • New Innovation Spurring a Biotech Rejuvenation
    Harvest Exchange22 days ago

    New Innovation Spurring a Biotech Rejuvenation

    Author Evan McCulloch Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund Since hitting an all-time high in July 2015, biotech stocks, as measured by the NASDAQ Biotechnology ...

  • Here Are the Key Products in Sage’s GABA Receptor Portfolio
    Market Realist23 days ago

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    As discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders through two different programs: GABA receptor systems and NMDA receptor systems.

  • Major Biotech ETFs Had Lackluster Performance in the Past Month
    Market Realistlast month

    Major Biotech ETFs Had Lackluster Performance in the Past Month

    All three major biotechnology ETFs—the SPDR S&P Biotech ETF (XBI), the iShares NASDAQ Biotechnology Index (IBB), and the ProShares Ultra Nasdaq Biotechnology ETF (BIB)—have posted returns of ~1% in last month, starting on August 10. That compares unfavorably with the performance of the SPDR S&P 500 ETF (SPY), which returned ~1.7% in the same period.

  • Investopedialast month

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in the first eight months of 2018 has created investment opportunities. These ETFs are poised to take advantage.

  • Bluebird Bio’s Valuation on September 6
    Market Realistlast month

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) is a clinical stage biotechnology company. It reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline YoY (year-over-year) compared to $16.72 million in the second quarter of 2017.

  • Considering Incyte’s Revenue Trend in Q2 2018
    Market Realist2 months ago

    Considering Incyte’s Revenue Trend in Q2 2018

    Incyte’s (INCY) consolidated revenue increased to $521.51 million in the second quarter compared to $326.44 million in the second quarter of 2017.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist2 months ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist2 months ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • What to Expect from Sarepta’s Second-Quarter Earnings
    Market Realist2 months ago

    What to Expect from Sarepta’s Second-Quarter Earnings

    Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company. Sarepta develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases.

  • Investopedia2 months ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • Biogen Stock Trending Higher on Strong Q2 2018 Results
    Market Realist3 months ago

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. The company’s sales and earnings came in ahead of Wall Street estimates. Biogen’s spinal muscular atrophy drug, Spinraza, registered sales of $423 million in Q2 2018, which almost doubled compared to the $203 million sales reported in Q2 2017.

  • MarketWatch3 months ago

    Biotech ETFs surge, supported by strong results from Biogen and Eli Lilly

    MARKET PULSE Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected quarterly results from a pair of major components. The iShares Nasdaq Biotechnology ETF (IBB) gained 1.

  • Investopedia3 months ago

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • What Investors Need to Know about Biotech ETFs
    Zacks3 months ago

    What Investors Need to Know about Biotech ETFs

    Smaller biotech stocks are outperforming this year; learn more about biotech ETFs best positioned to benefit